JPH0530813B2 - - Google Patents

Info

Publication number
JPH0530813B2
JPH0530813B2 JP60073394A JP7339485A JPH0530813B2 JP H0530813 B2 JPH0530813 B2 JP H0530813B2 JP 60073394 A JP60073394 A JP 60073394A JP 7339485 A JP7339485 A JP 7339485A JP H0530813 B2 JPH0530813 B2 JP H0530813B2
Authority
JP
Japan
Prior art keywords
coenzyme
phospholipids
cerebral anoxia
item
ubiquinone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP60073394A
Other languages
English (en)
Japanese (ja)
Other versions
JPS6133118A (ja
Inventor
Beruteri Aruberuto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ZOIREFU AG
Original Assignee
ZOIREFU AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ZOIREFU AG filed Critical ZOIREFU AG
Publication of JPS6133118A publication Critical patent/JPS6133118A/ja
Publication of JPH0530813B2 publication Critical patent/JPH0530813B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP7339485A 1984-04-09 1985-04-06 抗脳性酸素欠乏症代謝賦活剤 Granted JPS6133118A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH1774/84A CH661438A5 (it) 1984-04-09 1984-04-09 Composizioni farmaceutiche ad azione antianossica e metabolica cerebrale.
CH1774/84-7 1984-04-09

Publications (2)

Publication Number Publication Date
JPS6133118A JPS6133118A (ja) 1986-02-17
JPH0530813B2 true JPH0530813B2 (cg-RX-API-DMAC10.html) 1993-05-11

Family

ID=4218293

Family Applications (1)

Application Number Title Priority Date Filing Date
JP7339485A Granted JPS6133118A (ja) 1984-04-09 1985-04-06 抗脳性酸素欠乏症代謝賦活剤

Country Status (7)

Country Link
US (1) US4684520A (cg-RX-API-DMAC10.html)
JP (1) JPS6133118A (cg-RX-API-DMAC10.html)
CH (1) CH661438A5 (cg-RX-API-DMAC10.html)
DE (1) DE3417857C2 (cg-RX-API-DMAC10.html)
FR (1) FR2562422B1 (cg-RX-API-DMAC10.html)
GB (1) GB2157171B (cg-RX-API-DMAC10.html)
IT (1) IT1201412B (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12264593B1 (en) 2023-11-09 2025-04-01 Pratt & Whitney Canada Corp. Damped bladed rotor for gas turbine engine

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH661443A5 (en) * 1984-11-22 1987-07-31 Seuref Ag Pharmaceutical compositions having metabolic activity
JPH01305032A (ja) * 1988-06-01 1989-12-08 Sanwa Kagaku Kenkyusho Co Ltd 機能後退性消耗疾患治療予防剤及び飲食、し好物
JPH01305033A (ja) * 1988-06-01 1989-12-08 Sanwa Kagaku Kenkyusho Co Ltd 循環改善剤及び循環改善機能性食品並びにし好品
JPH02188523A (ja) * 1989-01-13 1990-07-24 M S C:Kk 睡眠時無呼吸症治療薬
US6461593B1 (en) * 1992-02-19 2002-10-08 Biomedical And Clinical Research Therapy with coenzyme Q10 to reduce subgingival microorganisms in patients with periodontal disease
AU5832794A (en) * 1993-01-06 1994-08-15 T.S. Consult Aps Medium comprising a pharmacological/biological active substance
US6312703B1 (en) 1998-02-06 2001-11-06 Lecigel, Llc Compressed lecithin preparations
US20030040505A1 (en) * 2000-03-31 2003-02-27 The Regents Of The University Of California Synthetic phospholipids to ameliorate atherosclerosis and other inflammatory conditions
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7144862B2 (en) * 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US6441050B1 (en) * 2000-08-29 2002-08-27 Raj K. Chopra Palatable oral coenzyme Q liquid
AUPR549901A0 (en) 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
BRPI0115953B8 (pt) * 2000-11-14 2021-05-25 Vital Health Sciences Pty Ltd complexos de derivados de fosfato
JP4745608B2 (ja) * 2001-07-27 2011-08-10 バイタル ヘルス サイエンシズ プロプライアタリー リミティド 電子伝達剤のリン酸誘導体を用いた皮膚治療
AUPR684801A0 (en) * 2001-08-06 2001-08-30 Vital Health Sciences Pty Ltd Supplement therapy
WO2003049774A1 (en) * 2001-12-13 2003-06-19 Vital Health Sciences Pty Ltd Transdermal transport of compounds
JP2003261456A (ja) * 2002-03-08 2003-09-16 Howaizu:Kk 脳の老化予防剤
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
BRPI0406484A (pt) * 2003-01-17 2005-12-06 Vital Health Sciences Pty Ltd Método de inibição da ocorrência de uma ou mais das seguintes condições: a proliferação de monócitos/macrófagos; ou a proliferação de células do músculo liso; ou a expressão de receptores de cd36; ou a absorção de lipoproteìna de baixa densidade - ldl oxidada, método de alìvio de sintomas de tratamento ou prevenção de aterosclerose; de diabetes; do mal de alzheimer, método de inibição da ocorrência da formação de placas no sistema vascular, método de alìvio da inflamação associada a ocorrência de uma ou de mais das seguintes condições: a proliferação de monócitos, a proliferação de células do músculo liso, a expressão de ldl oxidadas ou de receptor descontaminante, composição farmacêutica, uso de uma quantidade eficaz de um ou mais derivados ou fosfato de um ou mais agentes de transferência de elétrons conjuntamente com um veìculo ou um diluente apropriado, uso de uma quantidade eficaz de um ou mais derivados de fosfato de (alfa)-tocoferol conjuntamente com um veìculo ou um diluente apropriado e uso de uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais agentes de transferência de elétrons selecionados do grupo que consiste em fosfato mono-tocoferila, fosfato de di-tocoferila e as misturas destes conjuntamente com um veìculo ou um diluente apropriado
AU2003901815A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
US8252322B2 (en) * 2003-06-03 2012-08-28 Corn Products Development, Inc. Delivery system with increased bioavailability
TW200524541A (en) * 2003-11-17 2005-08-01 Cargill Inc Lecithin-containing granular compositions and methods of their preparation
US20060069157A1 (en) * 2004-02-19 2006-03-30 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as Huntington's disease, by sodium butyrate chemotherapy
AU2005202477B2 (en) * 2004-03-03 2005-12-15 Vital Health Sciences Pty Ltd Alkaloid formulations
CN101065137A (zh) * 2004-09-16 2007-10-31 加利福尼亚大学董事会 用于改善动脉粥样硬化和其它病变的g型多肽和其它剂
US7901675B2 (en) * 2004-10-13 2011-03-08 U.S. Department Of Veterans Affairs Method of using coenzyme Q10 to treat Huntington's disease
US7579319B2 (en) 2004-12-06 2009-08-25 The Regents Of The University Of California Methods for improving the structure and function of arterioles
US20060135612A1 (en) * 2004-12-17 2006-06-22 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
US20090233881A1 (en) * 2005-03-03 2009-09-17 Vital Health Sciences Pty. Ltd Compounds having anti-cancer properties
AU2006242651B2 (en) * 2005-04-29 2013-05-16 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
ES2557475T3 (es) * 2005-06-17 2016-01-26 Vital Health Sciences Pty Ltd. Un portador que comprende uno o más derivados di- y/o monofosfato de agentes de transferencia de electrones
DE102005056558B4 (de) * 2005-11-25 2009-04-30 Gisela Susilo Kombinationspräparate enthaltend physiologische Zellmembran-Bestandteile
EP1973547A1 (en) * 2005-12-23 2008-10-01 Vital Health Sciences Pty Ltd. Compounds having cytokine modulating properties
GB0603975D0 (en) * 2006-03-01 2006-04-05 Etren Methods and agents for reducing oxidative stress
CA2649315A1 (en) * 2006-04-10 2007-10-25 Mitsubishi Gas Chemical Company, Inc. Brain function-improving agent, and functional food containing the improving agent
WO2008062559A1 (en) * 2006-11-22 2008-05-29 Asahi Kasei Pharma Corporation Dietary supplement, anti-fatigue agent or physical endurance enhancer, functional food, or cosmetic
JP2010538005A (ja) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
EP2195340A4 (en) 2007-08-28 2011-05-11 Uab Research Foundation SYNTHETIC APOLIPOPROTEIN E-IMITATING POLYPEPTIDES AND METHOD OF USE
EP2531047B1 (en) 2010-02-05 2024-11-13 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
WO2011120084A1 (en) 2010-03-30 2011-10-06 Phosphagenics Limited Transdermal delivery patch
EP2685992A4 (en) 2011-03-15 2014-09-10 Phosphagenics Ltd AMINOCHINOLINE AS A KINASEHEMMER
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose
CA2954475C (en) 2014-07-31 2023-05-16 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
JP6882321B2 (ja) 2015-12-09 2021-06-02 フォスファージニクス リミテッド 医薬製剤
IL267006B2 (en) 2016-12-21 2024-11-01 Phosphagenics Ltd Process for phosphorylation of a complex alcohol with p4o10 at high temperatures, and products thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5938202B2 (ja) * 1976-03-05 1984-09-14 エーザイ株式会社 難聴治療剤
JPS5356315A (en) * 1976-11-01 1978-05-22 Eisai Co Ltd Emulsified solution of fat soluble drugs
US4221784A (en) * 1979-04-05 1980-09-09 Massachusetts Institute Of Technology Process and composition for treating disorders by administering lecithin
FR2472384A1 (fr) * 1979-12-27 1981-07-03 Sederma Sa Utilisation en cosmetologie de complexes naturels constitues d'ubiquinones et de phospholipides
JPS5742616A (en) * 1980-08-27 1982-03-10 Furointo Sangyo Kk Ubiquinone pharmaceutical having improved absorption
JPS5775916A (en) * 1980-10-29 1982-05-12 Nippon Chemiphar Co Ltd Coenzyme q pharmaceutical and its preparation
JPS57142911A (en) * 1981-02-28 1982-09-03 Furointo Sangyo Kk Absorption-improving agent
JPS58113127A (ja) * 1981-12-28 1983-07-05 Ajinomoto Co Inc ユビデカレノン含有水性液
CH649917A5 (en) * 1982-03-19 1985-06-28 Italfarmaco Sa Pharmaceutical formulations containing the coenzyme Q(10) suitable for topical administration
JPS58201711A (ja) * 1982-05-19 1983-11-24 Eisai Co Ltd ユビデカレノン含有リポソ−ム被覆体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12264593B1 (en) 2023-11-09 2025-04-01 Pratt & Whitney Canada Corp. Damped bladed rotor for gas turbine engine

Also Published As

Publication number Publication date
CH661438A5 (it) 1987-07-31
IT1201412B (it) 1989-02-02
GB2157171B (en) 1988-07-06
IT8520271A0 (it) 1985-04-05
GB2157171A (en) 1985-10-23
DE3417857C2 (de) 1997-04-24
US4684520A (en) 1987-08-04
FR2562422B1 (fr) 1989-03-31
FR2562422A1 (fr) 1985-10-11
DE3417857A1 (de) 1985-10-17
GB8508452D0 (en) 1985-05-09
JPS6133118A (ja) 1986-02-17

Similar Documents

Publication Publication Date Title
JPH0530813B2 (cg-RX-API-DMAC10.html)
FI85490B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara inositoltrifosfat.
EP0804183B1 (en) Use of creatine or creatine analogs for the treatment of huntigton's disease, parkinson's disease and amyotrophic lateral sclerosis
AU721190B2 (en) Use of creatine analogues for the treatment of disorders of glucose metabolism
AU759467B2 (en) Compositions containing a combination of a creatine compound and a second agent
US4757063A (en) Process for the treatment of diseases caused by oxidative stress
US5780489A (en) Method for treating amyotrophic lateral sclerosis
US6306392B1 (en) Composition comprising a carnitine and glutathione, useful to increase the absorption of glutathione and synergize its effects
Smith Paraquat toxicity
Flint Beal et al. Effects of Coenzyme Q 10 in Huntington's disease and early Parkinson's disease.
KR960001845B1 (ko) 헤테로사이클 치환된 디포스포네이트 화합물 및 이를 포함하는 약제학적 조성물
Kamisaka et al. Ligandin reverses bilirubin inhibition of liver mitochondrial respiration in vitro
EP0497906B1 (en) L-alpha-glycerophosphoryl-d-myo-inositol for the treatment of peripheral neuropathies and of cerebropathies
US20040057994A1 (en) Composition for the prevention and treatment of kidney dysfunctions and diseases
US6077838A (en) Method of treating hangover
US20230165824A1 (en) METHODS, SYSTEMS AND COMPOSITIONS FOR INHIBITION OF CELLULAR DYSFUNCTION AND CELL DEATH WITH DEUTERATED PUFAs
US4737489A (en) Method and composition for treating neurological disorders and aging
EP1010429B1 (en) Pharmaceutical composition, in particular for dietetical use comprising a derivative of pyruvic acid and unripe bitter orange extract
WO1990004400A1 (en) PROCESS FOR INCREASING PHOSPHATIDYLCHOLINE $i(IN VIVO)
CZ20004620A3 (cs) Přípravek obsahující karnitin a glutathion, vhodný pro zvýšení absorpce glutathionu a zesílení jeho účinků
JPS60214734A (ja) 脳内の神経伝達改善用組成物
AU2009208091A1 (en) Compositions containing a combination of a creatine compound and a second agent

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term